Glioblastoma cancer stem-like cells: Implications for pathogenesis and treatment

Cancer Journal

Volumn 18, Issue 1, 2012, Pages 100-106

  Nduom, Edjah Kweku Ebura ^a   Hadjipanayis, Costas George ^a,b,c   Van Meir, Erwin G ^a,c,d  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Georgia Cancer Coalition ^*  (United States)

^c EMORY UNIVERSITY   (United States)

^d Laboratory of Molecular Neuro oncology   (United States)

Author keywords

brain tumors; cancer stem cells; GBM; Glioblastoma; gliomagenesis; stem cells

Indexed keywords

CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CANCER STEM CELL; GLIOBLASTOMA; HEMATOPOIETIC CELL; HUMAN; NEURAL STEM CELL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; STEM CELL NICHE; TUMOR CELL;

BRAIN NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; NEOPLASTIC STEM CELLS;

EID: 84856741413     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e3182452e0d     Document Type: Review

References (78)

1. Brat DJ, Prayson RA, Ryken TC, et al. Diagnosis ofmalignant glioma: role ofneuropathology JNeurooncol. 2008;89:287-311.
2. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus con-comitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996. (Pubitemid 40349501)
3. Legler JM, Ries LA, Smith MA, et al. Cancer surveillance series [corrected]: brain and other central nervous system cancers: recent trends in incidence andmortality. J Natl Cancer Inst. 1999;91:1382-1390. (Pubitemid 29399996)
4. Brem H., Piantadosi S, Burger PC, et al. Placebo-controlled trial ofsafety and efficacy of intraoperative controlled delivery by biodegradable poly-mers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet. 1995;345:1008-1012.
5. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007;25:4722-4729. (Pubitemid 350086473)
6. Kelly PJ, Daumas-Duport C, Kispert DB, et al. Imaging-based stereo-taxic serial biopsies in untreated intracranial glial neoplasms. J Neurosurg. 1987;66:865-874. (Pubitemid 17085708)
7. Demuth T, Berens ME. Molecular mechanisms of glioma cell migration and invasion. J Neurooncol. 2004;70:217-228. (Pubitemid 39545733)
8. Hadjipanayis CG, Van Meir EG. Brain cancer propagating cells: biology genetics andtargetedtherapies. Trends Mol Med. 2009;15:519-530.
9. Fatoo A, Nanaszko MJ, Allen BB, et al. Understanding the role of tumor stem cells in glioblastoma multiforme: a review article. J Neurooncol. 2011;103:397-408.
10. Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med. 2006;355:1253-1261. (Pubitemid 44427449)
11. Hamburger AW, Salmon SE. Primary bioassay of human tumor stem cells. Science. 1977;197:461-463.
12. Ogawa M, Bergsagel DE, Mc Culloch EA. Differential effects ofmel-phalan on mouse myeloma (adj. PC-5) and hemopoietic stem cells. Cancer Res. 1971;31:2116-2119.
13. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature. 2004;432:396-401. (Pubitemid 39551674)
14. Salmaggi A, Boiardi A, Gelati M, et al. Glioblastoma-derived tumoro-spheres identify a population of tumor stem-like cells with angiogenic potential and enhanced multidrug resistance phenotype. Glia. 2006;54: 850-860. (Pubitemid 44671990)
15. Kang MK, Kang SK. Tumorigenesis ofchemotherapeutic drug-resistant cancer stem-like cells in brain glioma. Stem Cells Dev. 2007;16:837-847.
16. Facchino S, Abdouh M, Chatoo W, et al. BMI1 confers radioresistance to normal and cancerous neural stem cells through recruitment of the DNA damage response machinery. J Neurosci. 2010;30:10096-10111.
17. Hadjipanayis CG, Machaidze R, Kaluzova M, et al. EGFRv III antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma. Cancer Res. 2010;70:6303-6312.
18. Doetsch F, Caille I, Lim DA, et al. Subventricular zone astrocytes are neural stem cells in the adult mammalian brain. Cell. 1999;97:703-716. (Pubitemid 29278045)
19. Alvarez-Buylla A, Garcia-Verdugo JM, Tramontin AD. A unified hypoth-esis on the lineage of neural stem cells. Nat Rev Neurosci. 2001;2: 287-293. (Pubitemid 33673069)
20. Reynolds BA, Tetzlaff W, Weiss S. A multipotent EGF-responsive striatal embryonic progenitor cell produces neurons and astrocytes. J Neurosci. 1992;12:4565-4574.
21. Eriksson PS, Perfilieva E, Bjork-Eriksson T, et al. Neurogenesis in the adult human hippocampus. Nat Med. 1998;4:1313-1317. (Pubitemid 28512114)
22. Nunes MC, Roy NS, Keyoung HM, et al. Identification and isolation of multipotential neural progenitor cells from the subcortical white matter of the adult human brain. Nat Med. 2003;9:439-447. (Pubitemid 36460078)
23. Sanai N, Tramontin AD, Quinones-Hinojosa A, et al. Unique astrocyte ribbon in adult human brain contains neural stem cells but lacks chain migration. Nature. 2004;427:740-744. (Pubitemid 38294593)
24. Rao MS, Noble M, Mayer-Proschel M. A tripotential glial precursor cell is present in the developing spinal cord. Proc Natl Acad Sci U S A. 1998;95:3996-4001. (Pubitemid 28173242)
25. Mayer-Proschel M, Kalyani AJ, Mujtaba T, et al. Isolation of lineage-restricted neuronal precursors from multipotent neuroepithelial stem cells. Neuron. 1997;19:773-785. (Pubitemid 27471383)
26. Rhee W, Ray S, Yokoo H, et al. Quantitative analysis of mitotic Olig2 cells in adult human brain and gliomas: implications for glioma histo-genesis andbiology. Glia. 2009;57:510-523.
27. Sanai N, Alvarez-Buylla A, Berger MS. Neural stem cells and the origin ofgliomas. NEngl JMed. 2005;353:811-822.
28. Ignatova TN, Kukekov VG, Laywell ED, et al. Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers invitro. Glia. 2002;39:193-206.
29. Lee J, Kotliarova S, Kotliarov Y, et al. Tumor stem cells derived from glioblastomas cultured in b FGF and EGF more closely mirror the pheno-type and genotype ofprimary tumors than do serum-cultured cell lines. Cancer Cell. 2006;9:391-403. (Pubitemid 43668737)
30. Gursel DB, Beyene RT, Hofstetter C, et al. Optimization of glioblas-toma multiforme stem cell isolation, transfection, and transduction. J Neurooncol. 2011;104:509-522.
31. Guryanova OA, Wu Q, Cheng L, et al. Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3. Cancer Cell. 2011;19:498-511.
32. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003;63:5821-5828. (Pubitemid 37187480)
33. Beier D, Hau P, Proescholdt M, et al. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth charac-teristics and molecular profiles. Cancer Res. 2007;67:4010-4015. (Pubitemid 46815044)
34. Sakariassen PO, Prestegarden L, Wang J, et al. Angiogenesis-independent tumor growth mediated by stem-like cancer cells. Proc Natl Acad Sci US A. 2006;103:16466-16471. (Pubitemid 44715219)
35. Wang J, Sakariassen PO, Tsinkalovsky O, et al. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J Cancer. 2008;122:761-768.
36. Patrawala L, Calhoun T, Schneider-Broussard R, et al. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res. 2005; 65:6207-6219. (Pubitemid 40994406)
37. Goodell MA, Brose K, Paradis G, et al. Isolation and functional proper-ties ofmurine hematopoietic stem cells that are replicating in vivo. JExp Med. 1996; 183:1797-1806. (Pubitemid 26134320)
38. Broadley KW, Hunn MK, Farrand KJ, et al. Side population is not necessary or sufficient for a cancer stem cell phenotype in glioblastoma multiforme. Stem Cells. 2011;29:452-461.
39. Shen Q, Goderie SK, Jin L, et al. Endothelial cells stimulate self-renewal and expand neurogenesis of neural stem cells. Science. 2004; 304:1338-1340. (Pubitemid 38697433)
40. Ramirez-Castillejo C, Sanchez-Sanchez F, Andreu-Agullo C, et al. Pigment epithelium-derived factor is a niche signal for neural stem cell renewal. Nat Neurosci. 2006;9:331-339. (Pubitemid 43290962)
41. Calabrese C, Poppleton H, Kocak M, et al. A perivascular niche for brain tumor stem cells. Cancer Cell. 2007;11:69-82. (Pubitemid 46054518)
42. Christensen K, Schroder HD, Kristensen BW. CD133+ niches and single cells in glioblastoma have different phenotypes. J Neurooncol. 2011;104:129-143.
43. Charles N, Ozawa T, Squatrito M, et al. Perivascular nitric oxide acti-vates Notch signaling and promotes stem-like character in PDGF-induced gliomacells. Cell Stem Cell. 2010;6:141-152.
44. Keith B, Simon MC. Hypoxia-inducible factors, stem cells, and cancer. Cell. 2007;129:465-472. (Pubitemid 46660978)
45. Seidel S, Garvalov BK, Wirta V, et al. A hypoxic niche regulates glio-blastoma stem cells through hypoxia inducible factor 2 alpha. Brain. 2010;133(Pt4):983-995.
46. Pistollato F, Abbadi S, Rampazzo E, et al. Intratumoral hypoxic gradient drives stem cells distribution and MGMT expression in glioblastoma. Stem Cells. 2010;28:851-862.
47. Brat DJ, Van Meir EG. Glomeruloid microvascular proliferation orch-estrated by VPF/VEGF: a new world of angiogenesis research. Am J Pathol. 2001;158:789-796. (Pubitemid 32221771)
48. Hanahan D, Weinberg RA. Hallmarks ofcancer: the next generation. Cell. 2011;144:646-674.
49. Furnari FB, Fenton T, Bachoo RM, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007;21:2683-2710. (Pubitemid 350070717)
50. Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses ofhigh-grade glioma predict prognosis, delineate a pattern ofdisease progression, and resemble stages in neurogenesis. Cancer Cell. 2006;9:157-173. (Pubitemid 43357943)
51. Fotovati A, Abu-Ali S, Wang PS, et al. YB-1 bridges neural stem cells and brain tumor-initiating cells via its roles in differentiation and cell growth. Cancer Res. 2011;71:5569-5578.
52. Fulci G, Ishii N, Maurici D, et al. Initiation of human astrocytoma by clonal evolution of cells with progressive loss of p53 functions in a patient with a 283H TP53 germ-line mutation: evidence for a precursor lesion. Cancer Res. 2002;62:2897-2905. (Pubitemid 34525777)
53. Barnett SC, Robertson L, Graham D, et al. Oligodendrocyte-type-2 astrocyte (O-2A) progenitor cells transformed with c-myc and H-ras form high-grade glioma after stereotactic injection into the rat brain. Carcino-genesis. 1998;19:1529-1537. (Pubitemid 28441853)
54. Bachoo RM, Maher EA, Ligon KL, et al. Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal diff-erentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell. 2002;1:269-277. (Pubitemid 41039151)
55. Jin X, Yin J, Kim SH, et al. EGFR-AKT-Smad signaling promotes formation of glioma stem-like cells and tumor angiogenesis by ID3-driven cytokine induction. Cancer Res. 2011.
56. Alvarez-Buylla A, Jackson EL, Garcia-Verdugo JM, et al. PDGFR alpha-positive B cells are neural stem cells in the adult SVZ that form glioma-like growths in response to increased PDGF signaling. Neuron. 2006;51: 187-199. (Pubitemid 44063617)
57. Zhu Y, Guignard F, Zhao D, et al. Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocy-toma. Cancer Cell. 2005;8:119-130. (Pubitemid 41132741)
58. Rich JN. Cancer stem cells in radiation resistance. Cancer Res. 2007;67: 8980-8984. (Pubitemid 47535877)
59. Bao S, Wu Q, Sathornsumetee S, et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor Cancer Res. 2006;66:7843-7848. (Pubitemid 44299144)
60. Clement V, Sanchez P, de Tribolet N, et al. HEDGEHOG-GLI1 signal-ing regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity Curr Biol. 2007;17:165-172. (Pubitemid 46107823)
61. Donnenberg VS, Donnenberg AD. Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis. J Clin Pharmacol. 2005;45: 872-877. (Pubitemid 41060226)
62. Eberhart CG, Lim KJ, Bisht S, et al. A polymeric nanoparticle formul-ation of curcumin inhibits growth, clonogenicity and stem-like fraction in malignant brain tumors. Cancer Biol Ther. 2011;11:464-473.
63. Mehler MF, Mabie PC, Zhu G, et al. Developmental changes in pro-genitor cell responsiveness to bone morphogenetic proteins differen-tially modulate progressive CNS lineage fate. Dev Neurosci. 2000;22: 74-85. (Pubitemid 30098908)
64. Lee J, Son MJ, Woolard K, et al. Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells. Cancer Cell. 2008;13:69-80. (Pubitemid 350309742)
65. Piccirillo SG, Reynolds BA, Zanetti N, et al. Bone morphogenetic pro-teins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature. 2006;444:761-765. (Pubitemid 44949605)
66. Zhuang W, Li B, Long L, et al. Induction ofautophagy promotes differ-entiation of glioma-initiating cells and their radiosensitivity Int J Cancer. 2011;129:2720-2731.
67. Sunayama J, Sato A, Matsuda K, et al. Dual blocking of m Tor and PI3K elicits a prodifferentiation effect on glioblastoma stem-like cells. Neuro Oncol. 2010;12:1205-1219.
68. Zhu T, Costello MA, Talsma CE, et al. Endothelial cells create a stem cell niche in glioblastoma by providing Notch ligands that nurture self-renewal ofcancer stem-like cells. Cancer Res. 2011.
69. Ricci-Vitiani L, Pallini R, Biffoni M, et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature. 2010; 468:824-828.
70. Wang R, Chadalavada K, Wilshire J, et al. Glioblastoma stem-like cells give risue to tumour endothelium. Nature. 2010;468:829-U128.
71. Van Meir EG, Hadjipanayis CG, Norden AD, et al. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer JClin. 2010;60:166-193.
72. Hirano T, Akira S, Taga T, et al. Biological and clinical aspects of interleukin 6. Immunol Today. 1990;11:443-449.
73. Van Meir E, Sawamura Y, Diserens AC, et al. Human glioblastoma cells release interleukin 6 in vivo and in vitro. Cancer Res. 1990;50: 6683-6688. (Pubitemid 20348800)
74. Rahaman SO, Harbor PC, Chernova O, et al. Inhibition ofconstitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells. Oncogene. 2002;21:8404-8413. (Pubitemid 36054883)
75. Tzeng SY, Guerrero-Cazares H, Martinez EE, et al. Non-viral gene delivery nanoparticles based on poly(beta-amino esters) for treatment of glioblastoma. Biomaterials. 2011;32:5402-5410.
76. Chow KH, Gottschalk S. Cellular immunotherapy for high-grade glioma. Immunotherapy. 2011;3:423-434.
77. Avril T, Vauleon E, Hamlat A, et al. Human glioblastoma stem-like cells are more sensitive to allogeneic NK and T cell mediated killing compared to serum-cultured glioblastoma cells. Brain Pathol. 2011.
78. Ueda R, Ohkusu-Tsukada K, Fusaki N, et al. Identification of HLA-A2- and A24-restricted T-cell epitopes derived from SOX6 expressed in gliomastem cells forimmunotherapy. Int JCancer. 2010;126:919-929.